Scottish Funding OK For Breast Cancer Drugs Tukysa And Enhertu
Enhertu Recommendation From SMC Is Interim
Executive Summary
As well as recommending Seagen’s Tukysa and Daiichi Sankyo/AstraZeneca’s Enhertu, the Scottish Medicines Consortium has given the green light to Leo Pharma’s Adtralza and a new lung cancer indication for AZ’s Tagrisso. Meanwhile, Alexion has failed to make a submission to HTAs in both Scotland and England for a specific indication for Soliris.
You may also be interested in...
Seagen Wins Over English HTA Body With More Analyses & Lower Price For Tukysa
NICE now says that Tukysa should be made available on the National Health Service for advanced or metastatic breast cancer, and notes that the drug also offers “real hope” to people whose cancer has spread to their brain.
Blow For Seagen As England Rejects Funding For Advanced Breast Cancer Drug Tukysa
England’s health technology assessment body said it would continue to work with Seagen to address the reasons why its newly published draft guidance has recommended against using Tukysa on the National Health Service.
NICE Funding Wins For Enhertu & Kesimpta Are Firsts For England
UK health technology assessment body NICE has struck deals with the makers of Enhertu for advanced breast cancer and Kesimpta for relapsing forms of multiple sclerosis.